IP Library › Granted Patent US 12,415,847
Granted Patent B2
US 12,415,847 · App. 17/284,299 · Granted Sep 16, 2025

ApoM-Fc fusion proteins for treating lung diseases

Inventors: Timothy T. Hla (Wellesley, MA); Steven L. Swendeman (Cambridge, MA); Mark Puder (Medfield, MA); Lois Smith (West Newton, MA)
Assignee: Children's Medical Center Corporation
C07K14/775A61P11/00A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,415,847
App. No.
17/284,299
Granted
Sep 16, 2025
Kind
B2
Abstract

Provided herein are methods of treating lung disease using fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG).

Claims (22)

1. A method of decreasing the severity of one or more symptoms associated with bronchopulmonary dysplasia (BPD) or congenital diaphragmatic hernia (CDH), the method comprising administering to a subject in need thereof a therapeutically effective amount of a fusion protein comprising an apolipoprotein M (ApoM) fused to a constant region (Fc) of an immunoglobulin G (lgG), wherein the ApoM comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6, wherein the Fc comprises an amino acid sequence that is 96% identical to SEQ NO 7 or SEQ ID NO: 8.

2. The method of claim 1 , wherein the fusion protein further comprises a signal peptide fused to the ApoM.

3. The method of claim 1 , wherein the ApoM is fused at the N-terminus of the Fc.

4. The method of claim 1 , wherein the ApoM comprises the amino acid sequence of SEQ ID NO: 5.

5. The method of claim 1 , wherein the fusion protein comprises an amino acid sequence that is at least 96% identical to any one of SEQ ID NOs: 1-4 and 9.

6. The method of claim 1 , wherein the fusion protein is cross-linked, cyclized, conjugated, acylated, carboxylated, lipidated, acetylated, thioglycolic acid amidated, alkylated, methylated, polyglycylated, glycosylated, polysialylated, phosphorylated, adenylylated, PEGylated, or combinations thereof.

7. The method of claim 1 , wherein the fusion protein activates a SIP receptor.

8. The method of claim 1 , wherein the fusion protein is administered intravenously, intranasally, intratracheally, intramuscularly, or by inhalation.

9. The method of claim 1 , wherein the subject is human, and the ApoM comprises the amino acid sequence of SEQ ID NO:5 and the Fc comprises the amino acid sequence of SEQ ID NO 7.

10. The method of claim 9 , wherein the fusion protein is administered to the human subject in utero, within one hour to one year after birth, or when the human subject is an adult.

11. A method of decreasing the severity of one or more symptoms associated with Bronchopulmonary Dysplasia (BPD), the method comprising administering to a human subject in need thereof a therapeutically effective amount of a fusion protein comprising an apolipoprotein M (ApoM) fused to a constant region (Fc) of an immunoglobulin G (IgG), wherein the ApoM comprises the amino acid sequence of SEQ ID NO: 5, and wherein the Fc comprises the amino acid sequence of SEQ ID NO 7.

12. The method of claim 11 , wherein the human subject was born prematurely or was exposed to hyperoxia as a newborn.

13. The method of claim 11 , wherein the fusion protein is administered to the human subject in utero, within one hour to one year after birth, or when the human subject is an adult.

14. The method of claim 11 , wherein the fusion protein restores lung architecture.

15. A method of decreasing the severity of one or more symptoms associated with Congenital Diaphragmatic Hernia (CDH), the method comprising administering to a human subject in need thereof a therapeutically effective amount of a fusion protein comprising an apolipoprotein M (ApoM) fused to a constant region (Fc) of an immunoglobulin G (lgG), wherein the ApoM comprises the amino acid sequence of SEQ ID NO: 5, and wherein the Fc comprises the amino acid sequence of SEQ ID NO 7.

16. The method of claim 15 , wherein the fusion protein is administered to the human subject in utero, within one hour to one year after birth, or when the human subject is an adult.

17. The method of claim 15 , wherein the fusion protein increases lung regeneration and growth, and/or restores lung development.

18. The method of claim 1 , wherein the one or more symptoms associated with BPD or CDH are selected from the group consisting of: bluish skin, chronic cough, rapid breathing, and shortness of breath.

19. The method of claim 5 , wherein the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 1.

20. The method of claim 19 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 1.

21. The method of claim 5 , wherein the fusion protein comprises the amino acid sequence of any one of SEQ ID NOs: 1-4 and 9.

22. The method of claim 4 , wherein the Fc comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 7.

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 4, 2023
From: BOSTON CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065763/0750 →
Continuity (2)
Provisional Application 62744903 · Oct 12, 2018
Related Publication 20210380665A1 · Dec 9, 2021
References Cited (53)
US 10870689B2 · Hla et al. · 2020 [cited by applicant]
US 20110178029A1 · Knudsen et al. · 2011 [cited by applicant]
US 20130195849A1 · Spreter Von et al. · 2013 [cited by applicant]
US 20130324701A1 · Williams et al. · 2013 [cited by applicant]
US 20140303086A1 · Hla et al. · 2014 [cited by applicant]
US 20160184458A1 · Heartlein · 2016 [cited by examiner]
US 20170360749A1 · Harijith et al. · 2017 [cited by applicant]
US 20190185545A1 · Hla et al. · 2019 [cited by applicant]
US 20210032310A1 · Hla et al. · 2021 [cited by applicant]
CN 1556409A · 2004 [cited by applicant]
CN 101557817A · 2009 [cited by applicant]
CN 102858985A · 2013 [cited by applicant]
CN 105175553A · 2015 [cited by applicant]
JP 2020531010A · 2020 [cited by applicant]
WO WO2006000448A2 · 2006 [cited by applicant]
WO WO2010049103A1 · 2010 [cited by applicant]
WO WO2012162392A1 · 2012 [cited by applicant]
WO WO2017031353A1 · 2017 [cited by applicant]
WO WO2018052615A1 · 2018 [cited by applicant]
WO WO2019035931A1 · 2019 [cited by applicant]
Andersson-Sjoland et al., ROS-induced endothelial stress contributes to pulmonary fibrosis through pericytes and Wnt signaling, Laboratory Investigation; 96: 206-217. (Year: 2016). [cited by examiner]
Zhaorigetu et al., Perturbations in Endothelial Dysfunction-Associated Pathways in the Nitrofen-Induced Congenital Diaphragmatic Hernia Model, Journal of Vascular Research; 55: 26-34 (Abstract). (Year: 2017). [cited by examiner]
Green, The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD), Respiratory Research; 18(20). (Year: 2017). [cited by examiner]
Gorshkova et al., Inhibition of serine palmitoyltransferase delays the onset of radiation-induced pulmonary fibrosis through the negative regulation of sphingosine kinase-1 expression, Journal of Lipid Research vol. 53.… [cited by examiner]
Harajith et al. Sphingosine Kinase 1 Deficiency Confers Protection against Hyperoxia-Induced Bronchopulmonary Dysplasia in a Murine Model Role of S1P Signaling and Nox Proteins, The American Journal of Pathology, vol. 1… [cited by examiner]
Chen et al., The Sphingosine Kinase 1/Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension,American Journal of Respiratory and Critical Care Medicine vol. 190 No. 9. (Year: 2014). [cited by examiner]
Burg et al., Sphingosine-1 Phosphate Receptor-i-Mediated Endothelial Cell Barrier Function Protects Against Immune Complex-Induced Vascular Injury: A Potential Novel Therapeutic Target for SLE. Abstract 1790. 2017 ACR/A… [cited by examiner]
Kho et al., Am J Physiol Lung Cell Mol Physiol 305: L542-L554; doi: 10.1152/ajplung.00403.2012 (Year: 2013). [cited by examiner]
Hopkinsmedicine.org_-_BPD.pdf; examiner generated from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/bronchopulmonary-dysplasia (Year: 2024). [cited by examiner]
Hopkinsmedicine.org_-_CDH.pdf; examiner generated from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/congenital-diaphragmatic-hernia (Year: 2024). [cited by examiner]
Burg et al., Sphingosine 1-Phosphate Receptor 1 Signaling Maintains Endothelial Cell Barrier Function and Protects Against Immune Complex-Induced Vascular Injury. Arthritis Rheumatol. Nov. 2018;70(11):1879-1889. [cited by applicant]
Christoffersen et al., Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. Jun. 7, 2011;108(23):9613-8. [cited by applicant]
Kaplan et al., TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol. Mar. 15, 2000;164(6):2897-904. [cited by applicant]
Snoek et al., Sphingolipids in Congenital Diaphragmatic Hernia; Results from an International Multicenter Study. PLOS One. May 9, 2016;11(5). [cited by applicant]
Swendemen et al., An engineered S1P chaperone attenuates hypertension and ischemic injury. Sci Signal. Aug. 15, 2017;10(492). [cited by applicant]
Wang et al., Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its antitumor activity. Mol Cancer Ther. Mar. 2014;13(3):643-50. [cited by applicant]
Wu et al., Pharmacokinetics of Peptide-Fc fusion proteins. J Pharm Sci. Jan. 2014;103(1):53-64. doi: 10.1002/jps.23783. Epub Nov. 27, 2013. [cited by applicant]
Yu et al., Immunoglobulin Fc domain fusion to apolipoprotein (a) kringle V significantly prolongs plasma half-life without affecting its anti-angiogenic activity. Protein Eng Des Sel. Jun. 2013;26(6):425-32. [cited by applicant]
Zauner et al., Glycoproteomic analysis of antibodies. Mol Cell Proteomics. Apr. 2013;12 (4):856-65. [cited by applicant]
[No Author Listed] NCBI Protein Blast Sequence Comparison. Performed on Apr. 8, 2022. 1 page. [cited by applicant]
[No Author Listed] UniProt Database Accession No. P01857. UniProtKB-P01857 (IGHG1_Human). Immunoglobulin heavy constant gamma 1. First Available 1986. 20 pages. [cited by applicant]
[No Author Listed] Cambridge English Dictionary: “Artificial”. Accessed Dec. 19, 2022. 7 pages. https://dictionary.cambridge.org/us/dictionary /english/artificial. [cited by applicant]
[No Author Listed] GenBank Accession No. NP_061974.2. Apolipoprotein M Isoform 1. [cited by applicant]
[No Author Listed] GenBank Accession No. NP_061286.1. Apolipoprotein M Precursor. [cited by applicant]
Burg et al., Sphingosine-1 Phosphate Receptor-1-Mediated Endothelial Cell Barrier Function Protects Against Immune Complex-Induced Vascular Injury: A Potential Novel Therapeutic Target for SLE. Abstract 1790. 2017 ACR/A… [cited by applicant]
Christoffersen et al., The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem. Jul. 4, 2008;283(27):18765-72. [cited by applicant]
Zhaorigetu et al., Perturbations in Endothelial Dysfunction-Associated Pathways in the Nitrofen-Induced Congenital Diaphragmatic Hernia Model. J Vasc Res. 2018;55(1):26-34. doi: 10.1159/000484087. Epub Dec. 8, 2017. [cited by applicant]
CN 201880066972.7, Apr. 1, 2023, Chinese Office Action. [cited by applicant]
CN 201880066972.7, Nov. 23, 2023, Chinese Office Action. [cited by applicant]
CN 201780056922.6, Mar. 17, 2023, Chinese Office Action. [cited by applicant]
CN 201780056922.6, Jul. 7, 2023, Chinese Office Action. [cited by applicant]
Chen et al., Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci U S A. Dec. 22, 2009;106(51):21783-8. doi: 10.1073/pnas.0912274… [cited by applicant]
Sloud et al., Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. Mol Ther Methods Clin Dev. Nov. 4, 2015:2:15043. doi: 10.1038/mtm… [cited by applicant]